Ali Tehrani - Jul 15, 2021 Form 4 Insider Report for Zymeworks Inc. (ZYME)

Role
Chief Executive Officer, Director
Signature
/s/ Daniel Dex, Attorney-in-Fact
Stock symbol
ZYME
Transactions as of
Jul 15, 2021
Transactions value $
-$1,427,794
Form type
4
Date filed
7/16/2021, 09:30 PM
Previous filing
Jul 13, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZYME Common Shares Options Exercise $16.2K +3.8K +1.46% $4.27 264K Jul 15, 2021 Direct F1, F2
transaction ZYME Common Shares Sale -$137K -3.8K -1.44% $36.00* 260K Jul 15, 2021 Direct F1, F3
transaction ZYME Common Shares Options Exercise $176K +41.2K +15.82% $4.26 302K Jul 16, 2021 Direct F1, F4
transaction ZYME Common Shares Sale -$1.48M -41.2K -13.66% $36.00* 260K Jul 16, 2021 Direct F1, F3
holding ZYME Common Shares 55.5K Jul 15, 2021 Held by spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZYME Stock Option (Right to Buy) Options Exercise $0 -3.8K -8.45% $0.00 41.2K Jul 15, 2021 Common Shares 3.8K $4.27 Direct F1, F2, F5
transaction ZYME Stock Option (Right to Buy) Options Exercise $0 -41.2K -100% $0.00* 0 Jul 16, 2021 Common Shares 41.2K $4.26 Direct F1, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to a 10b5-1 plan entered into May 13, 2021.
F2 The exercise price of the stock option is CAD5.37. The U.S. dollar equivalent of the exercise price is $4.2713 using the Bank of Canada exchange rate for July 15, 2021 (CAD1.00 = $0.7954).
F3 All shares were sold at $36.00 per share.
F4 The exercise price of the stock option is CAD5.37. The U.S. dollar equivalent of the exercise price is $4.2643 using the Bank of Canada exchange rate for July 16, 2021 (CAD1.00 = $0.7941).
F5 Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date of January 1, 2012 and (ii) remainder of underlying shares in 36 equal monthly installments on the last day of month following first anniversary of grant date.